BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 10, 2018
View Archived Issues
JZTX-V, compound isolated from Chilobrachys spider, found to restore learning and memory in AD
Read More
Shanghai Longwood Biopharmaceuticals divulges JAK inhibitors
Read More
Medshine Discovery and collaborator patent MAP3K5 inhibitors
Read More
Yafei Shanghai Biomedical Technology divulges drug conjugates for cancer
Read More
Shenzhen Targetrx Biotechnology discloses Bcr-Abl1 inhibitors
Read More
FDA approves Jornay PM extended-release capsules for the treatment of ADHD
Read More
AstraZeneca discovers JAK1 inhibitors
Read More
IMV reaches important milestones in advanced ovarian cancer clinical trial
Read More
Epilepsy-associated de novo variants in GABRs alter GABA(A) receptor function
Read More
Inhibitors of "undruggable" enzymes induce tumor arrest
Read More
Gemphire Therapeutics halts pediatric NAFLD study of gemcabene
Read More
New review on glyphosate evaluating mechanisms, regulatory framework and research prospects
Read More
I-Mab cleared to conduct clinical trial of TJ-103 in China
Read More
Petrovax Pharm's 4-valeant influenza vaccine --Grippol Quadrivalent-- approved in Russia
Read More
Global phase III trial of Celltrion's bevacizumab biosimilar begins
Read More
FDA approves Arakoda for prevention of malaria
Read More
Basilea Pharmaceutica starts second registrational phase III study of ceftobiprole
Read More
Phase III study of JCR Pharmaceuticals' JR-141 for Hunter syndrome begins
Read More
